We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Siemens Healthineers - Laboratory Diagnostics

Download Mobile App

Next-Gen RNA-Based Liquid Biopsy Platform Detects Multiple Cancer Types at Earliest Stages

By LabMedica International staff writers
Posted on 08 Jun 2023
Print article
Image: Exai is developing blood tests that have both high accuracy and cancer biology insights (Photo courtesy of Freepik)
Image: Exai is developing blood tests that have both high accuracy and cancer biology insights (Photo courtesy of Freepik)

A novel RNA- and AI-based platform has demonstrated the ability to detect multiple cancer types at the earliest stages using a single, standard blood sample.

The universal platform developed by Exai Bio (Palo Alto, CA, USA) has diverse applications across numerous cancer care scenarios, including screening, early detection, monitoring, molecular residual disease analysis, and therapy selection. The platform employs RNA sequencing to distinguish a new class of small, non-coding RNAs linked to cancer, known as orphan non-coding RNAs (oncRNAs). The RNA composition of the transcriptome delivers a more dynamic and exhaustive perspective of actionable cancer biology than the DNA content of the genome. The abundance of oncRNAs in the blood of cancer patients and their relative scarcity in those without cancer makes oncRNA-based tests remarkably sensitive and specific.

Exai has identified hundreds of thousands of unique oncRNAs through studies involving over 16,000 patients, creating a vast catalog that paves the way for developing innovative RNA-based tests for early cancer detection. Exai utilizes artificial intelligence (AI) and machine learning (ML) to analyze the multitude of oncRNAs found in cancer patients' blood by identifying distinct, cancer-specific patterns. Exai has proven that these oncRNA patterns can be used to detect various types and subtypes of cancer, predict the original tissue of cancer, and identify cancer in its earliest stages.

In Exai’s multi-cancer early detection (MCED) study, eight types of cancer - lung, stomach, pancreas, kidney, colorectal, breast, prostate, and the bladder - were analyzed, reflecting the majority of the societal cancer burden. The study showed successful detection of stage I breast and prostate cancers, both of which have been extremely difficult to identify at early stages using other blood-based methods. When a cancer signal was identified in the test group, Exai's platform was able to pinpoint the origin tissue with 88% accuracy for the top predicted cancer type and 95% accuracy considering the top two predictions, demonstrating the power of its unique generative AI technology. This new MCED data lend further support to the increasing evidence that Exai's platform is versatile, and capable of application across numerous tumor types and clinical uses, all through the use of standard blood samples.

“These results demonstrate that Exai’s RNA- and AI-based platform can detect stage I cancer at very high sensitivity across multiple cancers while also maintaining the high specificity which is required for real-world clinical utility,” said Patrick Arensdorf, chief executive officer of Exai Bio. “Exai is developing blood tests that have both high accuracy and cancer biology insights to improve cancer care.”

Related Links:
Exai Bio

Platinum Supplier
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Gold Supplier
Automatic Western Blot Analyzer
Tenfly Phoenix Blot Analyzer
Silver Supplier
Real-time Fluorescence Quantitative PCR Analyzer
Tuberculosis Antibody Test
Tuberculosis lgG/lgM Rapid Test

Print article


Clinical Chemistry

view channel
Image: The new assays are designed to run on the B•R•A•H•M•S KRYPTOR compact PLUS clinical chemistry analyzer (Photo courtesy of Thermo Fisher)

Breakthrough Immunoassays to Aid in Risk Assessment of Preeclampsia

Preeclampsia is a life-threatening blood pressure condition that can arise during pregnancy and the postpartum phase. This severe pregnancy complication is a primary cause of maternal and fetal mortality... Read more


view channel
Image: The US FDA has cleared HemoScreen point of care CBC for direct capillary sampling (Photo courtesy of PixCell Medical)

Point of Care CBC Analyzer with Direct Capillary Sampling Enhances Ease-of-Use and Testing Throughput

The world’s only 5-part differential Complete Blood Count (CBC) analyzer that is FDA-cleared, CE-marked, and TGA-approved for point-of-care use has now been granted FDA 510(k) clearance for direct capillary... Read more


view channel
Image: Immune cells present long before infection predict flu symptoms (Photo courtesy of Shutterstock.com)

Single Blood Draw to Detect Immune Cells Present Months before Flu Infection Can Predict Symptoms

For decades, if not centuries, scientists have struggled to solve the mystery of why certain individuals fall ill to infections while others remain unaffected. In an impressive development, researchers... Read more


view channel
Image: The rapid diagnostic test could pinpoint the correct antibiotic for infection treatment in under an hour (Photo courtesy of Microplate Dx)

Point-of-Care Device to Reduce Antibiotic Susceptibility Testing Time from Days to Minutes

Antimicrobial resistance (AMR) is a significant global health issue, currently leading to over 1.27 million deaths worldwide each year. By 2050, AMR could be causing up to 10 million deaths annually, surpassing... Read more


view channel
Image: The Tasso+ device has received CE Mark certification (Photo courtesy of Tasso)

Groundbreaking Blood Lancing Device Obtains Microliter Capillary Whole Blood Samples Painlessly

A convenient, virtually pain-free blood lancet that collects whole liquid blood samples has received CE Mark designation, making the patient-centric, high-volume blood collection solution available in... Read more


view channel
Image: A new electrochemical device can quickly and inexpensively identify people at greatest risk for osteoporosis (Photo courtesy of ACS Central Science, 2023)

Electrochemical Device Identifies People at Higher Risk for Osteoporosis Using Single Blood Drop

With the global increase in life expectancy, the incidence of age-related conditions like osteoporosis is increasing. Osteoporosis, affecting around 200 million individuals worldwide, has a higher incidence... Read more


view channel
Image: The global fully automatic electrolyte analyzers market is projected to reach close to USD 0.77 billion by 2032 (Photo courtesy of 123RF)

Global Fully Automatic Electrolyte Analyzers Market Driven by Surge in Demand for Point-of-Care Testing

Fully automatic electrolyte analyzers can measure the levels of electrolytes in various bodily fluids like blood and plasma. Electrolytes are ions that have an electrical charge and are essential for multiple... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.